Patients with Lung Cancer Recommended Check Protein PDL-1

Jun 28, 2018 |

http://lsyindonesia.com/6-manfaat-bergabung-dengan-komunitas-kanker-payudara-bagi-penderita/

Patients with Lung Cancer Recommended Check Protein PDL-1

Based on Globocan 2012, lung cancer is the most common cancer and the most common cause of death in men and women in Indonesia. As exposed by specialist lung cancer and immunotherapy experts, dr. Sita Laksmi PhD, SpP (K) that from year to year the level of lung cancer patients is increasing, another case with other cancers actually decreased because some can be detected. With the immunotherapy treatment can provide insight in patients with advanced lung cancer (stage IV). Immunotherapy is a form of treatment that prevents the interaction between T cells belonging to the immune system and tumors. When tumors and T cells interact, a protein in a tumor called Programmed Death-Ligand 1 (PDL-1) will paralyze T cells so that these immune cells can not recognize and kill cancer cells.
Read also: Chronic Lung Disease Immunology, Safe If Fasting Through immunotherapy, this interaction can be blocked so that T cells can detect and eradicate cancer cells. Therefore, the importance of performing a PDL-1 examination if previous treatments such as chemotherapy, radiotherapy, or other treatment were unsuccessful
If the PDL-1 examination results are responsive it can be done immunotherapy, “” said Dr. Sita.Apabila when examination PDL-1 results are not responsive, it can not be done immunotherapy. Immunotherapy applied in Indonesia is as a second-line therapy
If the FDA (drug and food regulatory agency in America) has approve in people who have expressive / responsive PDL-1 over 50%. Having checked its PDL-1 expressively more than 50% of immunotherapy may be used as first line therapy. But in indonesia indication is still second line, stadarnya still chemotherapy, “” he said.Read also: Regent Sampang Tutup Age, Doctor: Lung Cancer
(up / up)

Posted in: Uncategorized